Global Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Report 2025: Outlook on Opportunities & Challenges

 Claim 30% Off With Code ONLINE30 — Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights

 

 How Is the Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Growth Forecast from 2025 to 2029?
 The artificial intelligence (AI)-powered rare disease diagnosis market size has grown exponentially in recent years. It will grow from $1.54 billion in 2024 to $1.99 billion in 2025 at a compound annual growth rate (CAGR) of 29.1%. The growth in the historic period can be attributed to increasing adoption of artificial intelligence (AI) in healthcare, growing investment in rare disease research, rising awareness about early diagnosis, expansion of healthcare infrastructure, and growing government support for digital health.
 
 The artificial intelligence (AI)-powered rare disease diagnosis market size is expected to see exponential growth in the next few years. It will grow to $5.50 billion in 2029 at a compound annual growth rate (CAGR) of 28.9%. The growth in the forecast period can be attributed to increasing integration of machine learning algorithms, rising demand for personalized medicine, growing collaboration between ai startups and hospitals, expansion of genomic data availability, increasing healthcare digitalization. Major trends in the forecast period include advancements in deep learning models, innovations in predictive diagnostics, developments in natural language processing for medical data, research and development in multi-omics integration, and continuous improvement in artificial intelligence (AI)-driven imaging technologies.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=28139&type=smp
 
  What Are the Key Growth Factors Supporting the Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Expansion?
 The increasing prevalence of autoimmune disorders is expected to propel the growth of the artificial intelligence (AI)-powered rare disease diagnosis market going forward. Autoimmune disorders are conditions where the immune system mistakenly attacks the body’s own healthy cells and tissues, causing inflammation and damage. The prevalence of autoimmune disorders is due to the growing number of individuals experiencing immune system dysfunctions, leading to higher demand for early diagnosis, advanced treatments, and continuous monitoring to manage symptoms effectively. Artificial intelligence (AI)-powered rare disease diagnosis supports autoimmune disorders management by rapidly identifying complex conditions, supporting personalized treatment decisions, and improving overall diagnostic accuracy. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government organization, in 2022, an estimated 514,000 people (2.0%) in Australia were living with the rheumatoid arthritis (a systemic autoimmune disorder in which the body’s immune system targets its tissues). Therefore, the increasing prevalence of autoimmune disorders drives the growth of the artificial intelligence (AI)-powered rare disease diagnosis market.
 
 What Segments Are Covered in the Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Report?
 The artificial intelligence (AI)-powered rare disease diagnosis market covered in this report is segmented as
 
 1) By Component: Software, Hardware, Services
 2) By Technology: Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Other Technologies
 3) By Deployment Mode: Cloud-Based, On-Premises
 4) By Diagnosis Type: Genetic Disorders, Autoimmune Disorders, Metabolic Disorders, Infectious Diseases, Other Diagnosis Types
 5) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users
 
 Subsegments:
 1) By Software: Clinical Decision Support, Data Analytics Platforms, Genomic Interpretation Tools, Machine Learning Algorithms, Diagnostic Reporting Software
 2) By Hardware: Sequencing Instruments, Imaging Devices, Laboratory Equipment, Computational Servers, Diagnostic Sensors
 3) By Services: Consulting Services, Implementation And Integration, Training And Support, Data Management Services, Maintenance And Upgrades
 
 What Are the Key Trends Shaping the Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
 Major companies operating in the artificial intelligence (AI)-powered rare disease diagnosis market are focusing on developing innovative technology, such as unified genomic diagnostics solutions, to enhance diagnostic accuracy, reduce turnaround time, and provide more comprehensive insights into complex genetic disorders. A unified genomic diagnostics solution is an integrated system combining whole-genome sequencing and artificial intelligence (AI)-driven analysis to deliver complete genetic insights. For instance, in October 2023, Oxford Nanopore Technologies plc, a UK-based biotechnology company, and Fabric Genomics Inc., a US-based artificial intelligence (AI)-based company, launched an integrated whole-genome sequencing solution that aims to accelerate rare disease diagnosis by combining rapid sequencing with AI-driven variant interpretation for more accurate and actionable clinical insights. The launch integrates real-time nanopore sequencing with artificial intelligence (AI)-powered genomic analysis to rapidly identify rare genetic variants. It delivers comprehensive, actionable insights to clinicians, enhancing diagnostic speed and accuracy for pediatric care.
 
 Who Are the Key Players Driving the Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market?
 Major companies operating in the artificial intelligence (ai)-powered rare disease diagnosis market are Ambry Genetics Corporation, MedGenome Inc., Sophia Genetics SA, Variantyx Inc., Facial Dysmorphology Novel Analysis, Atropos Health Inc., Congenica Ltd., Saventic Care Sp. z o.o., Rapid Innovation LLC, Centogene N.V., Impilo AB, ThinkGenetic Inc., ClairLabs Ltd., 3billion Inc., OpenEvidence Inc., GenomeUp S.R.L., Mendel.ai Inc., RareSum GmbH, DeepRare AI Solutions, Zebra-Llama Project.
 
 Get the full artificial intelligence (ai)-powered rare disease diagnosis market report here:
 https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-powered-rare-disease-diagnosis-global-market-report
 
 How Does Artificial Intelligence (AI)-Powered Rare Disease Diagnosis Market Growth Vary Across Major Regions?
 North America was the largest region in the artificial intelligence (AI)-powered rare disease diagnosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence (AI)-powered rare disease diagnosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company